Last reviewed · How we verify

NCT04013139

Relationship Between Cardiopulmonary Exercise Testing and Ca-P in Chronic Kidney Disease (CKD)

Completed Last updated 28 January 2022
What this trial tests

trial testing CPET in Ckd-Mbd in 200 participants. Completed in 1 October 2021.

Timeline
1 January 2020
Primary endpoint
1 August 2021
1 October 2021

Quick facts

Lead sponsorShahid Beheshti University of Medical Sciences
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date1 January 2020
Primary completion1 August 2021
Estimated completion1 October 2021
Sites1 location across Iran

Drugs / interventions tested

Conditions studied

Sponsor

Shahid Beheshti University of Medical Sciences

Who can join

18 and older, any sex, with Ckd-Mbd. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Reductions in exercise capacity associated with exercise intolerance augment cardiovascular disease risk and predict mortality in chronic kidney disease. This study utilized cardiopulmonary exercise testing to (a) investigate mechanisms of exercise intolerance; (b) unmask subclinical ca and p and vitamin D abnormalities that may precede cardiovascular disease in chronic kidney disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of CPET

Trials testing the same drug.

Other recruiting trials for Ckd-Mbd

Currently open trials in the same condition.

Other Shahid Beheshti University of Medical Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04013139.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing